



## Ocular Therapeutix™ to Present at the Cowen and Company 38th Annual Health Care Conference

February 28, 2018

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 28, 2018-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of Ocular Therapeutix, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:40 AM ET at the Boston Marriott Copley Place in Boston, Massachusetts.

In addition to the presentation, the management team will host investor meetings at the conference. Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen and Company representative.

A live webcast of the presentation can be accessed by visiting the Investors section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com).

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180228005367/en/>

Source: Ocular Therapeutix, Inc.

#### Investors

Ocular Therapeutix

Donald Notman

Chief Financial Officer

[dnotman@ocutx.com](mailto:dnotman@ocutx.com)

or

Westwicke Partners

Chris Brinze, 339-970-2843

[chris.brinze@westwicke.com](mailto:chris.brinze@westwicke.com)

or

#### Media

Ocular Therapeutix

Scott Corning

Vice President of Marketing & Commercial Operations

[scorning@ocutx.com](mailto:scorning@ocutx.com)